Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $28.57.
MarketBeat报道,目前报道该股的九家评级公司已将Nkarta, Inc.(纳斯达克股票代码:NKTX — Get Rating)的共识评级评级为 “适度买入”。一位股票研究分析师对该股进行了持有评级,八位对该公司给出了买入评级。去年涵盖该股的经纪商的1年平均价格目标为28.57美元。
Several brokerages recently weighed in on NKTX. Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They issued a "buy" rating and a $25.00 target price for the company. Oppenheimer downgraded shares of Nkarta from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 22nd. Mizuho dropped their price objective on shares of Nkarta from $81.00 to $26.00 and set a "buy" rating for the company in a research note on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a "buy" rating and a $25.00 price objective for the company.
最近有几家经纪公司对NKTX进行了权衡。Canaccord Genuity Group在10月10日星期一的一份研究报告中开始报道Nkarta的股票。他们为该公司发布了 “买入” 评级和25.00美元的目标价格。奥本海默在12月22日星期四的一份研究报告中将Nkarta的股票评级从 “跑赢大盘” 下调至 “市场表现”。瑞穗将Nkarta股票的目标价格从81.00美元下调至26.00美元,并在11月16日星期三的一份研究报告中为该公司设定了 “买入” 评级。最后,Canaccord Genuity Group在10月10日星期一的一份研究报告中开始报道Nkarta的股票。他们为公司设定了 “买入” 评级和25.00美元的价格目标。
Nkarta Trading Down 4.7 %
Nkarta 交易下跌 4.7%
Shares of NKTX stock opened at $5.07 on Tuesday. The firm has a 50-day moving average price of $7.07 and a 200 day moving average price of $11.43. Nkarta has a twelve month low of $4.83 and a twelve month high of $20.35. The company has a market capitalization of $247.49 million, a price-to-earnings ratio of -1.90 and a beta of 0.17.
周二,NKTX股票开盘价为5.07美元。该公司的50天移动平均价格为7.07美元,200天移动平均线价格为11.43美元。Nkarta创下十二个月低点4.83美元,十二个月高点为20.35美元。该公司的市值为2.4749亿美元,市盈率为-1.90,beta为0.17。
Institutional Trading of Nkarta
恩加达的机构交易
A number of institutional investors and hedge funds have recently bought and sold shares of NKTX. Parkwood LLC acquired a new stake in Nkarta during the 2nd quarter worth approximately $31,000. Quantbot Technologies LP increased its position in Nkarta by 39.1% during the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock worth $36,000 after purchasing an additional 900 shares in the last quarter. Denali Advisors LLC purchased a new position in Nkarta in the 2nd quarter worth approximately $38,000. Point72 Hong Kong Ltd purchased a new position in Nkarta in the 3rd quarter worth approximately $46,000. Finally, Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock worth $54,000 after acquiring an additional 4,147 shares during the period. Institutional investors and hedge funds own 87.22% of the company's stock.
许多机构投资者和对冲基金最近买入和卖出了 NKTX 的股票。Parkwood LLC在第二季度收购了Nkarta的新股份,价值约31,000美元。Quantbot Technologies LP在第一季度将其在Nkarta的头寸增加了39.1%。Quantbot Technologies LP在上个季度又购买了900股股票后,现在拥有该公司3,200股股票,价值36,000美元。Denali Advisors LLC在第二季度在恩卡塔购买了一个价值约38,000美元的新头寸。Point72 Hong Ltd在第三季度在Nkarta购买了一个价值约46,000美元的新头寸。最后,联邦爱马仕公司在第一季度将其在恩加达的持股量增加了735.3%。联邦爱马仕公司在此期间又收购了4,147股股票后,现在拥有该公司4,711股股票,价值54,000美元。机构投资者和对冲基金拥有该公司87.22%的股票。
Nkarta Company Profile
Nkarta 公司简介
(Get Rating)
(获取评分)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Nkarta, Inc是一家临床阶段的生物制药公司,开发和商业化用于癌症治疗的细胞疗法。该公司的细胞免疫疗法涉及自然杀伤(NK)细胞表面的嵌合抗原受体,使细胞能够识别肿瘤细胞表面存在的特定蛋白质或抗原。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
- 免费获取 StockNews.com 关于纳卡塔(NKTX)的研究报告的副本
- 诺斯罗普·格鲁曼公司的抛售是机会吗?
- 新首席执行官上任 Under Armor 股票的最差表现是否落后?
- 像 The Fit of Skechers USA
- 微软对ChatGBT的投资对MSFT股票意味着什么?
- 我们能相信标准普尔500指数的涨势吗
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Nkarta Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Nkarta及相关公司的最新新闻和分析师评级的简明每日摘要。